Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Jeong, Woondong
DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma Jul 2024 - Dec 2024 : Data for RRMM	Active, not recruiting	2	177	Europe, Canada, US, RoW	Belantamab mafodotin	GlaxoSmithKline	Multiple Myeloma	08/24	02/25
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)	Active, not recruiting	1/2	61	Europe, Japan, US, RoW	M1774, Tuvusertib, Cemiplimab	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Non-Small Cell Lung Cancer	05/25	02/26